CURRENT OPPORTUNITIES AND PROSPECTS OF CHEMOTHERAPY IN THE TREATMENT OF INTRACRANIAL MENINGIOMAS

Abstract

Background. The role of chemotherapy in the comprehensive treatment of intracranial meningiomas remains insufficiently defined. Although most meningiomas are benign, high recurrence rates, atypical and anaplastic variants, and limited surgical radicality in complex locations necessitate the development of adjuvant therapeutic strategies.
Objective. To analyze current evidence on the use of chemotherapy, hormonal therapy, and targeted pharmacological approaches in meningiomas of different grades.
Materials and Methods. A narrative review of international and national literature addressing chemosensitivity, molecular biology, growth factor signaling, hormone receptor expression, and radionuclide imaging in meningiomas was performed.
Results. Meningiomas demonstrate marked clonal, metabolic, and molecular heterogeneity, resulting in variable sensitivity to cytotoxic agents. Promising approaches include hydroxyurea, platinum-based chemotherapy, interferon therapy, and targeted inhibition of VEGF- and EGF-mediated pathways.
Conclusion. Despite the lack of randomized controlled trials, available clinical and experimental data suggest that further development of targeted and personalized chemotherapy may significantly improve outcomes in recurrent and malignant meningiomas.